GlassScriptPhysician profile
Cheryl J Barnes
NPI 1609838077
$5,552.87
in general payments reported to CMS, 2019-2025
36 companies · $1,604 in 2025
The $1,604 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $561 · 2020: $232 · 2021: $547 · 2022: $585 · 2023: $1,159 · 2024: $866 · 2025: $1,604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,329 · Education: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,329.32 |
| Education | $299.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,285.49 | 2019-2025 | Rinvoq, Skyrizi |
| Regeneron Healthcare Solutions, INC. | $689.20 | 2019-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $493.10 | 2019-2025 | Tremfya |
| Leo Pharma INC. | $395.12 | 2022-2025 | Adbry, Anzupgo |
| Pfizer INC. | $385.00 | 2019-2025 | |
| Genzyme Corporation | $216.00 | 2020-2025 | |
| Janssen Scientific Affairs, LLC | $209.44 | 2020-2021 | |
| Ucb, INC. | $192.21 | 2020-2025 | Bimzelx |
| Janssen Pharmaceuticals, INC | $177.17 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $164.99 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $150.65 | 2023-2025 | Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.61 | 2019-2025 | Spevigo, Ofev |
| Incyte Corporation | $112.40 | 2022-2024 | Opzelura |
| Seqirus USA INC | $88.18 | 2019-2025 | Flucelvax, Fluad |
| Organogenesis INC. | $86.25 | 2024-2025 | Apligraf, Affinity |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $81.44 | 2025 | Taltz, Ebglyss |
| Merck Sharp & Dohme LLC | $77.57 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $70.80 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $63.50 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $61.64 | 2022-2025 | |
| Novo Nordisk INC | $51.17 | 2021 | |
| Biofrontera INC. | $48.52 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Glaxosmithkline, LLC. | $43.39 | 2019-2025 | Shingrix, Arexvy |
| Dermavant Sciences, INC. | $37.79 | 2023 | Vtama |
| Amgen INC. | $29.03 | 2019-2024 | Otezla |
| Sanofi Pasteur INC. | $28.55 | 2023 | |
| Genentech USA, INC. | $24.12 | 2019 | |
| Sumitomo Pharma America, INC. | $22.92 | 2023 | Gemtesa |
| Arcutis Biotherapeutics, INC. | $18.72 | 2025 | Zoryve |
| Verrica Pharmaceuticals INC. | $18.35 | 2025 | Ycanth |
| Bayer Healthcare Pharmaceuticals INC. | $17.28 | 2022 | |
| Jazz Pharmaceuticals INC. | $16.41 | 2019 | |
| Galderma Laboratories, L.P. | $15.25 | 2025 | Nemluvio |
| Mallinckrodt Hospital Products INC. | $15.07 | 2022 | |
| Insmed, INC. | $13.70 | 2019 | |
| Phathom Pharmaceuticals, INC. | $6.84 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Barnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.